Indications for irradiation of blood components for prevention of TA-GVHD
Indication . | Institution . | ||
---|---|---|---|
MGH . | SBK/UHN . | HSC . | |
Stem cell transplant recipients | ✔ | ✔ | ✔ |
Congenital immunodeficiencies or infants with features suggestive of an undiagnosed immunodeficiency | ✔ | ✔ | ✔ |
Intrauterine transfusion | ✔ | ✔ | ✔ |
Premature, low birth weight | ✔ | ✔ | ✔ |
Term infants (<6 months old old) | ✔ | ✔ | |
Acute lymphoplastic leukemia | ✔ | ✔ | ✔ |
Other lymphoid malignancies | ✔ | ✔ | ✔ |
Acute myeloid leukemia | ✔ | ✔ | |
Chronic leukemias | ✔ | ✔ | |
Stem cell donors during harvest | ✔ | ||
Fludarabine, alemtuzumab, and ATG recipients | ✔ | ✔ | ✔ |
Children on intensive myeloablative chemotherapy regimens | ✔ | ✔ | |
Children with solid tumors or malignant hematologic disease | ✔ | ||
Children with solid organ transplants | ✔ |
Indication . | Institution . | ||
---|---|---|---|
MGH . | SBK/UHN . | HSC . | |
Stem cell transplant recipients | ✔ | ✔ | ✔ |
Congenital immunodeficiencies or infants with features suggestive of an undiagnosed immunodeficiency | ✔ | ✔ | ✔ |
Intrauterine transfusion | ✔ | ✔ | ✔ |
Premature, low birth weight | ✔ | ✔ | ✔ |
Term infants (<6 months old old) | ✔ | ✔ | |
Acute lymphoplastic leukemia | ✔ | ✔ | ✔ |
Other lymphoid malignancies | ✔ | ✔ | ✔ |
Acute myeloid leukemia | ✔ | ✔ | |
Chronic leukemias | ✔ | ✔ | |
Stem cell donors during harvest | ✔ | ||
Fludarabine, alemtuzumab, and ATG recipients | ✔ | ✔ | ✔ |
Children on intensive myeloablative chemotherapy regimens | ✔ | ✔ | |
Children with solid tumors or malignant hematologic disease | ✔ | ||
Children with solid organ transplants | ✔ |
HSC, Hospital for Sick Children, Toronto, Canada; MGH, Massachusetts General Hospital, Boston, MA; SBK, Sunnybrook Health Sciences Centre, Toronto, Canada; UHN, University Health Network, Toronto, Canada.